← SynDRA
APALUTAMIDE
SynDRA canonical compound SYN0037912 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | AR |
|---|
| Mechanism of action | Androgen receptor antagonist |
|---|
| Indication | prostate cancer |
|---|
| Disease area | oncology |
|---|
All known targets
Mechanisms of action (all sources)
- AR ANTAGONIST
- AR INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- ATXN2
- CP2C9
- GABRP
- GABRG3
- GABRG2
- GABRG1
- GABRE
- GABRD
- GABRB3
- GABRB2
- GABRB1
- GABRA6
- GABRA5
- GABRA4
- GABRA3
- GABRA2
- GABRA1
- GABRQ
ATC classes
- L02B · HORMONE ANTAGONISTS AND RELATED AGENTS
Cross-references
Synonyms
- ERLEADA
- Erleada
- ARN-509
- JNJ-56021927
- erleada
- Apalutamida
- Arn-509 (AR inhibitor)
- ARN 509
- 4T36H88UA7
- JNJ 56021927
- ARN509
- apalutamida
- apalutamidum
- RefChem:58966
- DTXCID20164390
- L02BB05
- Apalutamide [INN]
- Apalutamide (ARN-509)
- UNII-4T36H88UA7
- MFCD22380626
- C21H15F4N5O2S
- Erleada (TN)
- ApalutamideARN509?
- Apalutamide (Standard)
- Apalutamide (JAN/INN)
- APALUTAMIDE [MI]
- APALUTAMIDE [JAN]
- APALUTAMIDE [WHO-DD]
- MLS006011109
- SCHEMBL909297
- GTPL9043
- orb1305642
- SCHEMBL29351392
- SCHEMBL29396285
- APALUTAMIDE [ORANGE BOOK]
- EX-A089
- GLXC-90445
Reported adverse events
- Fall
- Hypothyroidism
- Seizure
- Arthralgia
- Fatigue
- Fracture
- Hypertension
- Injury
- Leukopenia
- Lymphopenia
- Nausea
- Pruritus
Look up APALUTAMIDE in the interactive SynDRA portal →